Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Receivables - Net: 2010-2024

Historic Receivables - Net for OptimizeRx (OPRX) over the last 15 years, with FY2024 value amounting to $38.2 million.

  • OptimizeRx's Receivables - Net rose 2241.05% to $32.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.2 million, marking a year-over-year increase of 2241.05%. This contributed to the annual value of $38.2 million for FY2024, which is 540.37% up from last year.
  • As of FY2024, OptimizeRx's Receivables - Net stood at $38.2 million, which was up 540.37% from $36.3 million recorded in FY2023.
  • OptimizeRx's Receivables - Net's 5-year high stood at $38.2 million during FY2024, with a 5-year trough of $17.9 million in FY2020.
  • Moreover, its 5-year median value for Receivables - Net was $24.8 million (2021), whereas its average is $27.9 million.
  • Its Receivables - Net has fluctuated over the past 5 years, first surged by 14111.14% in 2020, then tumbled by 1066.62% in 2022.
  • Annual analysis of 5 years shows OptimizeRx's Receivables - Net stood at $17.9 million in 2020, then soared by 38.66% to $24.8 million in 2021, then fell by 10.67% to $22.2 million in 2022, then surged by 63.63% to $36.3 million in 2023, then rose by 5.4% to $38.2 million in 2024.
  • Its last three reported values are $38.2 million in FY2024, $36.3 million for FY2023, and $22.2 million during FY2022.